BIOA

BioAge Labs, Inc. Common Stock

5.78

USD

+0.09

+1.58%

Nov 10, 15:59 UTC -5

Closed

After-Market

5.79

+0.01

+0.17%

BioAge Labs, Inc. Common Stock (BIOA) Earnings

BIOA Earnings Reports

Positive Surprise Ratio

BIOA beat 6 of 9 last estimates.

67%

Next Report

Date of Next Report

Mar 22, 2027

Estimate for Q4 26 (Revenue/ EPS)

$1.38M

-$0.69

Implied change from Q3 26 (Revenue/ EPS)

+363.22%

-5.48%

Implied change from Q4 25 (Revenue/ EPS)

-55.15%

-4.17%

BioAge Labs, Inc. Common Stock earnings per share and revenue

On Nov 05, 2026, BIOA reported earnings of -0.73 USD per share (EPS) for Q3 26, missing the estimate of -0.64 USD, resulting in a -13.39% surprise. Revenue reached 298.00 thousand, compared to an expected 1.68 million, with a -82.23% difference. The market reacted with a -3.61% price change (close before vs. close after earnings).

Looking ahead to Q4 26, -- analysts forecast an EPS of -0.69 USD, with revenue projected to reach 1.38 million USD, implying an decrease of -5.48% EPS, and increase of 363.22% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Kura Oncology, Inc.

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.83

Actual

-$0.78

Surprise

+7.00%

Olema Pharmaceuticals, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.63

Actual

-$0.73

Surprise

-14.53%

Autolus Therapeutics plc - ADR

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.21

Surprise

-27.20%

Protalix BioTherapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.03

Actual

$0.05

Surprise

+265.02%

PepGen Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.28

Surprise

-1.19%

Humacyte, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.09

Actual

-$0.07

Surprise

+22.91%

Seer, Inc. Class A Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.25

Actual

-$0.25

Surprise

+1.96%

Scholar Rock Holding Corporation Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.86

Actual

-$0.81

Surprise

+6.18%

TELA Bio, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.13

Surprise

+20.54%

Atossa Therapeutics, Inc. Common Stock

Report Date

Nov 10, 2026 For Q3 26

Estimate

-$0.90

Actual

-$0.56

Surprise

+38.31%

FAQ

What were BioAge Labs, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, BioAge Labs, Inc. Common Stock reported EPS of -$0.73, missing estimates by -13.39%, and revenue of $298.00K, -82.23% below expectations.

How did the market react to BioAge Labs, Inc. Common Stock's Q3 2026 earnings?

The stock price moved down -3.61%, changed from $5.54 before the earnings release to $5.34 the day after.

When is BioAge Labs, Inc. Common Stock expected to report next?

The next earning report is scheduled for Mar 22, 2027.

What are the forecasts for BioAge Labs, Inc. Common Stock's next earnings report?

Based on -- analysts, BioAge Labs, Inc. Common Stock is expected to report EPS of -$0.69 and revenue of $1.38M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.